AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
Launch of 20 new medicines expected by 2030. Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios. Investing in disruptive innovation that will shape the future of medicine and drive long-term growth. Decoupling carbon emissions from revenue growth.Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology, biopharmaceuticals and rare disease portfolio, and by launching an expected 20 new medicines before the end of